Opinion|Videos|April 22, 2024
Advice for Clinicians Administering Bispecifics to Patients With R/R MM
Author(s)Caitlin Costello, MD, Matthew James Pianko, MD
Drs Costello and Pianko close their discussion by sharing advice for clinicians administering bispecifics to their patients with relapsed/refractory multiple myeloma.
Advertisement
Episodes in this series
Advertisement
Related to this article
C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.
Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.
Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.
![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“We should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
How Well Does Radiotherapy Pair With Dual PD-1/LAG-3 Blockade in NSCLC?
2
Expanding CAR T and Bispecific Antibody Research in HIV-Associated Lymphoma
3
Ubamatamab Yields Responses in Recurrent Low-Grade Serous Ovarian Cancer
4
FDA OKs Pirtobrutinib in Frontline CLL/SLL
5